- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Dr Hope Rugo: Advances in HER2-Positive Breast Cancer
Hope Rugo, MD, director of the breast oncology clinical trials program at the University of California at San Francisco, discusses advances in the treatment of HER2-positive breast cancer.
Transcript:
Is there anything you’re working on or excited about in HER2-positive breast cancer that you’d like to share?
We're working on a number of different things. One is trying to move neratinib earlier in the adjuvant course and seeing if we can manage the diarrhea with a novel agent. So that’s one trial my colleague Joe Chen is working on.
In terms of the metastatic setting, there are a number of novel agents, oral TKIs [tyrosine-kinase inhibitors], and then an antibody—drug conjugate from Daiichi which has shown responses in patients who had highly resistant disease, at least as reported to trastuzumab. That’s going into a phase 3 trial this year. Then there’s a novel antibody that binds to the receptors a bit differently called margetuximab that’s in a phase 3 trial called the SOPHIA trial. That drug also showed responses in phase 1 studies in patients who had disease resistant to trastuzumab.
So, I think there’s a number of different agents out there which seem as though they have potential for the future.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Q&A With Dr Chelsee Jensen: Navigating FDA Approvals, Challenges in the Biosimilar Landscape
January 14th 2024Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, reacts to the biggest FDA approvals of 2023 and how she sees the adalimumab, natalizumab, and tocilizumab spaces playing out.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
IGBA 2023: Dr Monique Mansoura Highlights the Intersection of Geopolitical Issues, Biopharma
February 19th 2023COVID-19 allowed governments to critically examine the biopharma space to increase access to vaccines, but there's still a way to go, according to Monique Mansoura, PhD, MBA, executive director of global health security and biotechnology at the MITRE Corporation, at the International Generic and Biosimilar Medicines Association’s annual meeting.
